The Australian Government has announced an important update that will make treatment more affordable for people with cerebral palsy.
As outlined in a recent media release from The Hon Mark Butler MP, the medication IncobotulinumtoxinA (Xeomin®) will now be available to more people through the Pharmaceutical Benefits Scheme (PBS).
This treatment is used to help manage spasticity, a common symptom of cerebral palsy that affects muscle movement and can make everyday tasks more difficult. By helping muscles relax, this medication can support improved comfort, mobility and independence.
For many families, cost has been a barrier. Without subsidy, this treatment can cost over $1,400 per script. Under the PBS, eligible patients will now pay a maximum of $25, or $7.70 with a concession card.
This change is expected to support thousands of Australians with cerebral palsy to access treatment more easily.
To read the full announcement, visit the original media release from the Australian Government.
